ODH Therapeutics FRPP Information Document

Updated: April 14, 2022

Some COVID-19 therapeutics are coordinated through HHS for state-coordinated distribution Additional information on the state-coordinated distribution is available here.

A side-by-side comparison of the therapeutics with administration, authorized uses, cost/payment and product-specific information is available (<u>link</u>). All sites should review the Health & Human Services Therapeutics Clinical Implementation Guide (<u>link</u>) for critical information about the administration of these therapeutics.

ODH Contact Information

The ODH Therapeutics Team can be reached at therapeutics@odh.ohio.gov.

Enrollment Process

Interested facilities may request enrollment in the oral therapeutics FRPP program through the ODH Therapeutics Desk. Facilities must provide the following information to the ODH Therapeutics desk at therapeutics@odh.ohio.gov:

- Name of pharmacy chain
- Primary and secondary contacts (phone number and email)
- Number of requested weekly courses

Approved partners can expect to begin receiving product two weeks after the completion of enrollment.

Reporting Requirements

Sites are required to report in HPOP daily when open. Documentation on updating the therapeutic courses administered and available is here (https://docs.oracle.com/en/industries/health-sciences/vpop-partner/vpopc/update-therapeutic-courses-administered-and-available-provider-newtopic.html).

Sites that do not submit data to US Health & Human Services through the above reports may have therapeutic allocations paused while the site resumes reporting. Questions about reporting can be directed to therapeutics@odh.ohio.gov.

Therapeutics Locator

The U.S. Department of Health and Human Services maintains the COVID-19 Therapeutics Locator. Locator data changes with distributions and is preliminary as sites come online and is not real-time. The locator can be found here: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

Wastage

All products requiring cold-chain, must maintain cold-chain compliance after receipt from AmerisourceBergen. Sites that repeatedly report wastage or with unaccounted courses may have their allocations paused until mitigation measures can be put in place to prevent additional wastage. These products come at a significant expense and effective product stewardship is needed for all sites.

Report wastage to therapeutics@odh.ohio.gov. A mechanism within HPOP is available and a member of the ODH Therapeutics Desk will direct you on its usage.

Reference Documents Available

- HPOP Provider Portal Quick Start Guide (link)
- Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 (link)
- HHS Therapeutics Clinical Implementation Guide (<u>link</u>)